Send to

Choose Destination
Sci Transl Med. 2017 Mar 8;9(380). pii: eaaf6413. doi: 10.1126/scitranslmed.aaf6413.

An oral microjet vaccination system elicits antibody production in rabbits.

Aran K1,2,3,4, Chooljian M5,6,3, Paredes J5,3,7, Rafi M5, Lee K5,6, Kim AY5, An J5, Yau JF5, Chum H8, Conboy I5,6,4, Murthy N1,6,3, Liepmann D1,6,3.

Author information

Department of Bioengineering, University of California (UC), Berkeley, Berkeley, CA 94720, USA.
School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA 91711, USA.
Berkeley Sensor and Actuator Center, Berkeley, CA 94720, USA.
Buck Institute for Research on Aging, Novato, CA 94945, USA.
Department of Bioengineering, University of California (UC), Berkeley, Berkeley, CA 94720, USA.
UC Berkeley-UC San Francisco Graduate Program in Bioengineering, Berkeley and San Francisco, CA 94158, USA.
Center of Studies and Technical Research of Gipuzkoa and Tecnun (Technological Campus of the University of Navarra), 20018 San Sebasti√°n, Spain.
Office of Laboratory Animal Care, UC Berkeley, Berkeley, CA 94720, USA.


Noninvasive immunization technologies have the potential to revolutionize global health by providing easy-to-administer vaccines at low cost, enabling mass immunizations during pandemics. Existing technologies such as transdermal microneedles are costly, deliver drugs slowly, and cannot generate mucosal immunity, which is important for optimal immunity against pathogens. We present a needle-free microjet immunization device termed MucoJet, which is a three-dimensional microelectromechanical systems-based drug delivery technology. MucoJet is administered orally, placed adjacent to the buccal tissue within the oral cavity, and uses a self-contained gas-generating chemical reaction within its two-compartment plastic housing to produce a high-pressure liquid jet of vaccine. We show that the vaccine jet ejected from the MucoJet device is capable of penetrating the buccal mucosal layer in silico, in porcine buccal tissue ex vivo, and in rabbits in vivo. Rabbits treated with ovalbumin by MucoJet delivery have antibody titers of anti-ovalbumin immunoglobulins G and A in blood serum and buccal tissue, respectively, that are three orders of magnitude higher than rabbits receiving free ovalbumin delivered topically by a dropper in the buccal region. MucoJet has the potential to accelerate the development of noninvasive oral vaccines, given its ability to elicit antibody production that is detectable locally in the buccal tissue and systemically via the circulation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center